aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Sudo Biosciences, a biopharmaceutical company, was founded with the mission to design and develop novel, best-in-class medicines aimed at transforming patients' lives. The company focuses on targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, a key mediator in cytokine signaling pathways linked to various immune-mediated inflammatory conditions. Sudo Biosciences' pipeline includes next-generation TYK2 inhibitors, positioning them as potential first- and best-in-class therapeutics in this area.
Notable figures affiliated with Sudo Biosciences include leading scientists and industry experts who drive the company's innovative research and development efforts. The company has garnered attention from prominent investors in the biopharmaceutical sector, reflecting confidence in its groundbreaking approach. Key achievements include advancing their lead programs through critical development stages, which underscores their potential impact on treating immune-mediated inflammatory diseases. Sudo Biosciences continues to make significant strides in biopharmaceutical innovation, aiming to improve patient outcomes globally.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics, Medicines
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software, Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Sudo Biosciences founded?
Sudo Biosciences was founded in 2020.
Where is Sudo Biosciences's headquarters located?
Sudo Biosciences's headquarters is located in Menlo Park, CA, US.
When was Sudo Biosciences's last funding round?
Sudo Biosciences's most recent funding round was for $116M (USD) in December 2023.
How many employees does Sudo Biosciences have?
Sudo Biosciences has 11 employees as of Feb 5, 2024.
How much has Sudo Biosciences raised to-date?
As of July 05, 2023, Sudo Biosciences has raised a total of $153M (USD) since Dec 20, 2023.
Add Comparison
Total Raised to Date
$153M
USD
Last Update Dec 20, 2023
Last Deal Details
$116M
USD
Dec 20, 2023
Series B
Total Employees Over Time
11
As of Feb 2024
Sudo Biosciences Address
70 Willow Rd.
Suite 200
Menlo Park,
California
94025
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts